Healthcare

Neurizon said the expanded cohort preserves the original statistical power and does not change its funding needs. It now expects topline results in late Q4 of the 2027 financial year, which it equates to late in the second quarter of calendar 2027, earlier than …

Nexsen said the joint venture device targets hospitals and labour wards, while its own StrepSure product targets antenatal screening and clinics with limited laboratory access, so the two would serve different settings and price points. Nexsen would lead Asia-Pacific sales outside China and would …

The company said 1,174,004 new CDIs are to be issued on 30 October 2026. They will rank equally with existing CDIs and are expected to begin trading on the ASX on 2 November 2026. The plan follows a placement announced on 21 September 2026 …

Trajan describes itself as a global developer and manufacturer of analytical and life sciences products and devices. It employs about 600 people across seven manufacturing sites in the United States, Australia, Europe and Malaysia. Its segments are Components and Consumables, which is the core, …

Under the Versiti arrangement, two Guardion devices will go to the partner's research institute in Milwaukee. Vitrafy said deployments to its partners are under way this quarter. Guardion is the company's device for freezing and storing blood products, and LifeChain is the accompanying software.

Quarterly sales were up 30 per cent on the same quarter a year earlier. Over the last twelve months, sales reached US$25.1 million, also up 30 per cent, which the company described as an acceleration from 26 per cent growth in the twelve months …

The company said 1,174,004 new CDIs are to be issued on 30 October 2026. They will rank equally with existing CDIs and are expected to begin trading on the ASX on 2 November 2026. The plan follows a placement announced on 21 September 2026 …